drugset / Trial / NCT00174590

Treatment of Major Depressive Disorder With Psychotic Features.

NCT00174590

Phase 3 Terminated 30 enrolled Rush University Medical Center Janssen, LP · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of risperidone monotherapy in the treatment of psychotic depression. We hypothesize that risperidone is as equally as effective as haloperidol plus sertraline for depression with psychotic features

Timeline

Start
2001-09
Primary completion
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified